NRG-GY029, "A Randomized Phase II Trial Comparing the Combination of PI3K Inhibitor Copanlisib (BAY 80-6946) with PARP Inhibitor Olaparib (AZD2281) to Standard Chemotherapy in Patients with Recurrent Platinum Resistant Ovarian, Fallopian, Tube, or Primary Peritoneal Cancer Who Have Progressed Through Prior PARP Inhibitor Therapy" (NCT TBD)
Details
Age
Adult
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Lindsay Brubaker, MD
Study ID
Protocol Number: 22-1568
More information available at ClinicalTrials.gov: NCT05295589
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers